Ipsilateral Recurrence of DCIS in Relation to Radiomics Features on Contrast Enhanced Breast MRI

Overview

Journal Tomography

Publisher MDPI

Specialty Radiology

Date 2022 Mar 22

PMID 35314626

Authors

Ga Eun Park

Sung Hun Kim

Eun Byul Lee

Yoonho Nam

Wonmo Sung

Affiliations

Soon will be listed here.

Abstract

The purpose of this retrospective study was to investigate the association between ipsilateral recurrence of ductal carcinoma in situ (DCIS) and radiomics features from DCIS and contralateral normal breast on contrast enhanced breast MR imaging. A total of 163 patients with DCIS who underwent preoperative MR imaging between January 2010 and December 2014 were included (training cohort; n = 117, validation cohort; n = 46). Radiomics features were extracted from whole tumor volume of DCIS on early dynamic T1-subtraction images and from the contralateral normal breast on precontrast T1 and early dynamic T1-subtraction images. After feature selection, a Rad-score was established by LASSO Cox regression model. Performance of Rad-score was evaluated by the receiver operating characteristic (ROC) curve and Kaplan Meier curve with log rank test. The Rad-score was significantly associated with ipsilateral recurrence free survival (RFS). The low-risk group with a low Rad-score showed higher ipsilateral RFS than the high-risk group with a high Rad-score in both training and validation cohorts (p < 0.01). The Rad-score based on radiomics features from DCIS and contralateral normal breast on breast MR imaging showed the potential for prediction of ipsilateral RFS of DCIS.

Citing Articles

Feasibility analysis of magnetic resonance imaging-based radiomics features for preoperative prediction of nuclear grading of ductal carcinoma in situ.

Zhao M, Ma W, Song X, Li Z, Shao Z, Lu H Gland Surg. 2023; 12(9):1209-1223.

PMID: 37842532 PMC: 10570967. DOI: 10.21037/gs-23-132.

Freehand 1.5T MR-Guided Vacuum-Assisted Breast Biopsy (MR-VABB): Contribution of Radiomics to the Differentiation of Benign and Malignant Lesions.

Tagliafico A, Calabrese M, Brunetti N, Garlaschi A, Tosto S, Rescinito G Diagnostics (Basel). 2023; 13(6).

PMID: 36980315 PMC: 10047866. DOI: 10.3390/diagnostics13061007.

How Radiomics Can Improve Breast Cancer Diagnosis and Treatment.

Pesapane F, De Marco P, Rapino A, Lombardo E, Nicosia L, Tantrige P J Clin Med. 2023; 12(4).

PMID: 36835908 PMC: 9963325. DOI: 10.3390/jcm12041372.

Quantitative Imaging in Oncology.

Sung W Tomography. 2022; 8(4):1676-1677.

PMID: 35894004 PMC: 9326774. DOI: 10.3390/tomography8040139.

References

Wapnir I, Dignam J, Fisher B, Mamounas E, Anderson S, Julian T . Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011; 103(6):478-88. PMC: 3107729. DOI: 10.1093/jnci/djr027. View

Lee E, Kim S, Park G, Lee J, Kang B . Risk Stratification of Ductal Carcinoma In Situ and Texture Analysis of Contrast-Enhanced Breast Magnetic Resonance Imaging. J Comput Assist Tomogr. 2021; 45(6):843-848. DOI: 10.1097/RCT.0000000000001205. View

Castellano G, Bonilha L, Li L, Cendes F . Texture analysis of medical images. Clin Radiol. 2004; 59(12):1061-9. DOI: 10.1016/j.crad.2004.07.008. View

Allegra C, Aberle D, Ganschow P, Hahn S, Lee C, Millon-Underwood S . National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst. 2010; 102(3):161-9. DOI: 10.1093/jnci/djp485. View

Cuzick J, Sestak I, Pinder S, Ellis I, Forsyth S, Bundred N . Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2010; 12(1):21-9. PMC: 3018565. DOI: 10.1016/S1470-2045(10)70266-7. View

Barrio A, Van Zee K . Controversies in the Treatment of Ductal Carcinoma in Situ. Annu Rev Med. 2017; 68:197-211. PMC: 5532880. DOI: 10.1146/annurev-med-050715-104920. View

Materka A . Texture analysis methodologies for magnetic resonance imaging. Dialogues Clin Neurosci. 2011; 6(2):243-50. PMC: 3181797. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

Waugh S, Purdie C, Jordan L, Vinnicombe S, Lerski R, MARTIN P . Magnetic resonance imaging texture analysis classification of primary breast cancer. Eur Radiol. 2015; 26(2):322-30. DOI: 10.1007/s00330-015-3845-6. View

10.

Nam Y, Park G, Kang J, Kim S . Fully Automatic Assessment of Background Parenchymal Enhancement on Breast MRI Using Machine-Learning Models. J Magn Reson Imaging. 2020; 53(3):818-826. DOI: 10.1002/jmri.27429. View

11.

Fox M, Gibbs P, Pickles M . Minkowski functionals: An MRI texture analysis tool for determination of the aggressiveness of breast cancer. J Magn Reson Imaging. 2015; 43(4):903-10. DOI: 10.1002/jmri.25057. View

12.

Bijker N, Meijnen P, Peterse J, Bogaerts J, Van Hoorebeeck I, Julien J . Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative.... J Clin Oncol. 2006; 24(21):3381-7. DOI: 10.1200/JCO.2006.06.1366. View

13.

Dontchos B, Rahbar H, Partridge S, Korde L, Lam D, Scheel J . Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?. Radiology. 2015; 276(2):371-80. PMC: 4554209. DOI: 10.1148/radiol.2015142304. View

14.

Donker M, Litiere S, Werutsky G, Julien J, Fentiman I, Agresti R . Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013; 31(32):4054-9. DOI: 10.1200/JCO.2013.49.5077. View

15.

Arasu V, Miglioretti D, Sprague B, Alsheik N, Buist D, Henderson L . Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk. J Clin Oncol. 2019; 37(12):954-963. PMC: 6494266. DOI: 10.1200/JCO.18.00378. View

16.

Henderson S, Purdie C, Michie C, Evans A, Lerski R, Johnston M . Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer. Eur Radiol. 2017; 27(11):4602-4611. PMC: 5635097. DOI: 10.1007/s00330-017-4850-8. View

17.

Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson L, Sandelin K . Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008; 26(8):1247-52. DOI: 10.1200/JCO.2007.12.7969. View

18.

Kim S, Cho N, Ryu E, Seo M, Bae M, Chang J . Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery. Radiology. 2013; 270(3):699-707. DOI: 10.1148/radiol.13130459. View

19.

Grimm L . Breast MRI radiogenomics: Current status and research implications. J Magn Reson Imaging. 2015; 43(6):1269-78. DOI: 10.1002/jmri.25116. View

20.

Li J, Song Y, Xu S, Wang J, Huang H, Ma W . Predicting underestimation of ductal carcinoma in situ: a comparison between radiomics and conventional approaches. Int J Comput Assist Radiol Surg. 2018; 14(4):709-721. DOI: 10.1007/s11548-018-1900-x. View